BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate an anti-tumor immune response.

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

A customer who sought $1.75 million from a Portland nail salon — alleging that it spread the genital herpes virus during a ...

MRIs are expensive, but the benefit can far outweigh the cost to help diagnose injuries in athletes, sports medicine ...